DDrare: Database of Drug Development for Rare Diseases

95. 自己免疫性肝炎
［臨床試験数：44，薬物数：57（DrugBank：26），標的遺伝子数：18，標的パスウェイ数：108］

Searched query = "Autoimmune hepatitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = AZATHIOPRINE; Abatacept; Anti-BAFFR antibody; Anti-BAFFr antibody; Azathioprine; Budesonide; Calcium; Cannabidiol; Chloroquine; Chloroquine diphosphate; Chloroquine diphosphate 250mg; Cyclosporin; Cyclosporin A; Cyclosporine; Cyclosporine-A; Denosumab; EFALIZUMAB; Efalizumab; Erythropoietin; Gold; High protein high fiber diet; INTERLEUKIN 2; Ianalumab; Inflectra (Infliximab); Infliximab; Interleukin 2; JKB-122; JKB-122 in capsule or tablet form; LCP-Tacro (tacrolimus); MYCOPHENOLATE MOFETIL; Metronidazole; Minodronic acid; Mycophenolate; Mycophenolate Mofetil; Mycophenolate mofeti; Mycophenolate mofetil; Orbcel-C; Orencia® (Abatacept); PREDNISOLONE SODIUM SUCCINATE; Prednisolone; Prednisone; Preimplantation factor; Raptiva; Raptiva 100 mg/ml powder and solvent for solution for injection; Regulatory T cells; Risedronic acid; SPIF; Synthetic PreImplantation Factor; Tacrolimus; Treatment with azathioprin; Treatment with mycophenolat mofetil; Ursodeoxycholic Acid; Ursodeoxycholic acid; Ursodeoxycholic acid combination of immunosuppressive agents; VAY736; Vitamin D; Zoledronic acid

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03593460 (ClinicalTrials.gov)	January 1, 2019	7/6/2018	Phase II AutoImmune Hepatitis	Phase II, Open Label, Adaptive Design, Multiple Dose Finding Study to Investigate Synthetic PreImplantation Factor (sPIF) in Patients With Autoimmune Hepatitis (AIH)	Hepatitis, Autoimmune	Drug: Synthetic PreImplantation Factor	Christopher O'Brien, MD	BioIncept LLC	Withdrawn	18 Years	75 Years	All	0	Phase 2	NULL
2	NCT02239562 (ClinicalTrials.gov)	November 14, 2014	10/9/2014	sPIF CLINICAL STUDY PROTOCOL IN AUTOIMMUNE HEPATITIS	A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of Synthetic PreImplantation Factor (sPIF) in Autoimmune Hepatitis	Autoimmune Hepatitis	Drug: sPIF;Drug: Placebo	Christopher O'Brien, MD	BioIncept LLC	Completed	18 Years	70 Years	Female	36	Phase 1	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT03593460
(ClinicalTrials.gov)

January 1, 2019

7/6/2018

Phase II AutoImmune Hepatitis

Phase II, Open Label, Adaptive Design, Multiple Dose Finding Study to Investigate Synthetic PreImplantation Factor (sPIF) in Patients With Autoimmune Hepatitis (AIH)

Hepatitis, Autoimmune

Drug: Synthetic PreImplantation Factor

Christopher O'Brien, MD

BioIncept LLC

Withdrawn

18 Years

75 Years

All

Phase 2

NULL

NCT02239562
(ClinicalTrials.gov)

November 14, 2014

10/9/2014

sPIF CLINICAL STUDY PROTOCOL IN AUTOIMMUNE HEPATITIS

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of Synthetic PreImplantation Factor (sPIF) in Autoimmune Hepatitis

Autoimmune Hepatitis

Drug: sPIF;Drug: Placebo

Christopher O'Brien, MD

BioIncept LLC

Completed

18 Years

70 Years

Female

Phase 1

United States